Das ist ein sehr gutes Ergebnis!
Diese Artikel beschreiben nur geringe Nebenwirkungen auch bei wiederholter Anwendung, allerdings auch die von Dir erwähnte Kraftlosigkeit:
Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy
und
The impact of repeated cycles of radioligand therapy using [177Lu]Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer.
"Conclusion: Even after repeated therapy cycles [bis zu sechs], Lu-PSMA did not cause significant (CTC 3° or 4°) nephrotoxicity in patients. Among the markers for the assessment of renal function, TER-MAG3 and cystatin C showed the best predictive accuracy for renal impairment after therapy."
Georg
Diese Artikel beschreiben nur geringe Nebenwirkungen auch bei wiederholter Anwendung, allerdings auch die von Dir erwähnte Kraftlosigkeit:
Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy
und
The impact of repeated cycles of radioligand therapy using [177Lu]Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer.
"Conclusion: Even after repeated therapy cycles [bis zu sechs], Lu-PSMA did not cause significant (CTC 3° or 4°) nephrotoxicity in patients. Among the markers for the assessment of renal function, TER-MAG3 and cystatin C showed the best predictive accuracy for renal impairment after therapy."
Georg
Kommentar